Tailoring cancer care for older adults isn’t “extra” — it’s better care. Proud of our team for showing that geriatric oncology can be implemented successfully in the community and meaningfully improve end-of-life outcomes:

ADCs: guided missiles, slow chemo infusion, or something else? In our latest free-access commentary, led by Matthew Vogel and just out in @JCO_ASCO, we review the latest evidence on ADCs’ mechanism of action, diving deep into their fascinating complexity. ascopubs.org/doi/10.1200/JCO…

🔔Take a look at this article now published @NatureCancer ! 'Tumor antigens preferentially derive from unmutated genomic sequences in #melanoma and non-small cell #lungcancer' ✏️By Pierre Thibault, Claude Perreault and colleagues 🔗nature.com/articles/s43018-0…

A commenter writes, "This makes my blood boil with anger." Learn why he is right about a NIH funded study published in NEJM sensible-med.com/p/a-new-cos…

I really don’t think people realize how incredibly hard and complex real cancer is to treat. Oncologists would happily treat their dying patients with this. It just isn’t true that there’s a simple off the shelf generic that magically cures all cancers.

WELCOME: Dr. Matthew Hess to the Department of Orthopaedic Surgery! Hess is 1 of only 2 specialists trained in pediatric & adult orthopaedic surgical oncology in Alabama. More: uab.edu/medicine/orthopaedic… @UABHeersink @uabmedicine @ONealCancerUAB @ChildrensAL @VABIRMINGHAM @UABNews

#myeloMATCH clinical trials are now open at @DukeCancer, using advanced biomarker testing to optimize therapy for patients with #AML & #MDS. An @theNCI precision medicine endeavor led by Duke's own Dr. #HarryErba and Dr. Richard Little of the NCI. swog.org/myelomatch-overview

A positive trial for cancer cachexia - a very distressing symptom to patients and caregivers! Congrats to my bud @MDRoeland for being an @NEJM author

Less than half of cancer drugs approved based on a surrogate endpoint are ever found to improve survival in their entire lifecycle. ncbi.nlm.nih.gov/pmc/article…

An Interview with the Nature editor who rejected the paper that won the Nobel Prize In mid-2000s, Katalin Karikó submitted one of her papers to Nature, the prestigious academic journal. Nature desk rejected her paper saying that it did not offer any original insights and that Karikó’s work only makes an “incremental” contribution to the field. The paper was later published in another academic journal Immunity and eventually became the basis for Karikó’s work that won her the Nobel Prize in physiology. I tracked down the Nature editor who desk rejected Karikó’s paper and asked how he felt about Karikó winning the Nobel Prize. Following is an excerpt of my conversation with the Nature editor who spoke to me on the condition of anonymity. The conversation has been edited for mockery and ridicule. Mushtaq Bilal (MB): Good afternoon! I hope it’s not too awkward a moment for you. Nature Editor (NE): Just another day in the life of a journal editor who rejected potentially Nobel Prize winning work. MB: How do you feel about being the editor who rejected that paper? Did you ever think something like this might happen? NE: Oh Absolutely! I have a sixth sense for these things. I can spot a Nobel Prize winning paper from a mile away…and then reject it. MB: Good to know you still have a sense of humor… NE: …and a bit of false pride too. MB: Have you considered adding it to your CV, “Professional Rejector of Groundbreaking Work?” NE: That’s a good one. I am thinking of starting a new journal called “Nature Rejected” in which I will publish every paper rejected by Nature. MB: Sounds like a best-seller to me… NE: I could’ve been the editor who published the Nobel Prize winning work, I could’ve become the next star in academia. Nobel Prize winning scientist would mention my in their speeches, invite me to go to Sweden with them where I would get myself nice, relaxing Swedish massages…that’s my biggest regret, Mushtaq. I was so looking forward to those massages. MB: I think we are getting off track a bit. Coming back to the paper, walk us through the day you rejected that paper. NE: It was just another day. I woke up, applied for a few non-academic jobs, dropped my kids at school, fought with my wife over wet towels, had lunch followed by a huge relaxing fart, and then I rejected the paper. MB: Some details are a bit unnecessary but let’s not get off topic again. Have to thought of sending a congratulatory message to Karikó? Maybe a fruit basket with a “My bad” card? NE: That would be the class thing to do. I’m thinking of sending her a telescope. So, the next time she spots something groundbreaking, she can magnify it enough for even me to see. MB: That makes no sense… NE: I know. It’s a shit joke… MB: It’s actually quite refreshing to see someone like you who owns up to their mistakes. NE: Thanks. And please send me the transcript of this interview so I could take a look at it before you post? MB: Why, you want to reject it too?

neat use of existing data to ask clinically meaningful question. I just had this come up in my VA clinic last week

Our prospective study showing body composition differences among NH Black and NH white patients with GI cancer. @GrantWilliamsMD @smith__giri @DHESS280 @MFowlerPhD authors.elsevier.com/a/1iniY…

#MedTwitter Join us for a ~blast~ with this Hematology VMR! We will be joined by the infamous Papa Heme @AaronGoodman33 discussing a hematology case with Heme/Onc Fellow extraordinaire @chefaleixomd! We can’t wait to see you tomorrow, Feb. 19 at 9pm EST! bit.ly/31LWIKg

With our highly modular VELOCIREPTORS, we can generate >30,000 different types of self-propelled CAR T cells designed to infiltrate solid tumors. We test 5 in mouse models of pancreatic/ovarian/lung cancer, 3 cancers with poor survival rates. Here: biorxiv.org/content/10.1101/…

@DHESS280 @smith__giri @GrantWilliamsMD Sarcopenia scores and relationship to OS #gerionc #SIOG2022

How to beat Imposter Syndrome. 5 steps to have the career you want: